Targeted Cancer Therapy for Patients With 17p Deletion
Time: 2:00 pm
day: Day One
Details:
- Discussing Del(17p) as a potential platform-wide predictive biomarker for amanitin based ADCs
- Highlighting superior efficacy of amanitin based ADCs in cancer models with 17p loss
- Outlining the expedited clinical development of HDP-101 for Del(17p) patients
